TaiRx, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Taipei Taiwan (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2015
NCT02507544
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

TaiRx, Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

nivolumab (opdivo) (1 trial)

sorafenib (nexavar) (1 trial)

trx-818 (5 trials)

Drugs in Phase 1 Trials (2)

cvm-1118 (1 trial)

sn-38 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 5